BIOX

Bioceres Crop SolutionsA

Nasdaq / Materials

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$0.70

+99.9% vs current

Most likely

Base case

45%

Probability

Target price

$0.30

-14.3% vs current

B-

Bear case

40%

Probability

Target price

$0.12

-65.7% vs current

AI sentiment snapshot

Latest data as of 2026-07-19

AI commentary

This is a low-coverage, low-conviction monitoring view. The updated company release and SEC materials remain predominantly cautious: weak Q3 results, limited liquidity, going-concern uncertainty, and adverse litigation developments outweigh partial Rizobacter liability-management progress. The anchor price was $0.3501 on 2026-07-17. Quantified social coverage, reliable analyst revisions, and strong direct peers are unavailable, so missing revision data is not positive evidence.

RankAlpha Sentiment Codex - 2026-07-19

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-01eventRizobacter debt exchange offers partial liability-management supportHigh impact

Rizobacter completed an exchange offer covering approximately $42.7 million of notes, with participation of about 86% of outstanding principal. This improves maturity-management optics but does not resolve parent-level litigation or financing risk. [#SEC-6K-2026-06-01]

2026-06-19eventLitigation and short-term debt remain decisive downside risksHigh impact

The June 19 Form 6-K disclosed an additional $3.4 million provision and a court ruling finding multiple defaults, valid acceleration, and liability for the company and guarantors; damages and related foreclosure issues remain unresolved. [#SEC-6K-2026-06-19]

2026-08-15catalystUpdated Q3 results keep near-term pressure elevatedHigh impact

The company’s updated fiscal Q3 release reported revenue down 23% year over year to $39.4 million, gross profit of $12.7 million, a $13.4 million net loss, and adjusted EBITDA of negative $0.6 million. Crop Nutrition grew 15%, while Crop Protection fell 18% and Seeds and Integrated Products fell 71%. [#PR-2026-06-19]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-19 • Updated nightlySource: Internal modelMethodology